AAAAAA

   
Results: 1-16 |
Results: 16
Acute myeloid leukemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis
Authors: Kolte, B Baer, AN Sait, SNJ O'Loughlin, KL Stewart, CC Barcos, M Wetzler, M Baer, MR
Citation: B. Kolte et al., Acute myeloid leukemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis, LEUK LYMPH, 42(3), 2001, pp. 371-378
HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse
Authors: Wetzler, M Baer, MR Stewart, SJ Donohue, K Ford, L Stewart, CC Repasky, EA Ferrone, S
Citation: M. Wetzler et al., HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse, LEUKEMIA, 15(1), 2001, pp. 128-133
High-dose cytosine arabinoside and idarubicin treatment of chronic myeloidleukemia in myeloid blast crisis
Authors: Barone, S Baer, MR Sait, SNJ Lawrence, D Block, AW Wetzler, M
Citation: S. Barone et al., High-dose cytosine arabinoside and idarubicin treatment of chronic myeloidleukemia in myeloid blast crisis, AM J HEMAT, 67(2), 2001, pp. 119-124
Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecularweight heparin
Authors: Simon, M Hahn, T Ford, LA Anderson, B Swinnich, D Baer, MR Bambach, B Bernstein, SH Bernstein, ZP Czuczman, MS Slack, JL Wetzler, M Herzig, G Schriber, J McCarthy, PL
Citation: M. Simon et al., Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecularweight heparin, BONE MAR TR, 27(6), 2001, pp. 627-633
Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia
Authors: Xia, Z Sait, SNJ Baer, MR Barcos, M Donohue, KA Lawrence, D Ford, LA Block, AMW Baumann, H Wetzler, M
Citation: Z. Xia et al., Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia, LEUK RES, 25(6), 2001, pp. 473-482
A novel serine-dependent proteolytic activity is responsible for truncatedsignal transducer and activator of transcription proteins in acute myeloidleukemia blasts
Authors: Xia, Z Salzler, RR Kunz, DP Baer, MR Kazim, L Baumann, H Wetzler, M
Citation: Z. Xia et al., A novel serine-dependent proteolytic activity is responsible for truncatedsignal transducer and activator of transcription proteins in acute myeloidleukemia blasts, CANCER RES, 61(4), 2001, pp. 1747-1753
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
Authors: Stone, RM Berg, DT George, SL Dodge, RK Paciucci, PA Schulman, PP Lee, EJ Moore, JO Powell, BL Baer, MR Bloomfield, CD Schiffer, CA
Citation: Rm. Stone et al., Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine, BLOOD, 98(3), 2001, pp. 548-553
Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia
Authors: Bunworasate, U Arnouk, H Minderman, H O'Loughlin, KL Sait, SNJ Barcos, M Stewart, CC Baer, MR
Citation: U. Bunworasate et al., Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia, BLOOD, 98(12), 2001, pp. 3492-3494
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
Authors: Baer, MR Stewart, GC Dodge, RK Leget, G Sule, N Mrozek, K Schiffer, CA Powel, BL Kolitz, JE Moore, JO Stone, RM Davey, FR Carrol, AJ Larson, RA Bloomfield, CD
Citation: Mr. Baer et al., High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361), BLOOD, 97(11), 2001, pp. 3574-3580
NCCN Practice Guidelines for acute myelogenous leukemia
Authors: O'Donnell, MR Appelbaum, FR Baer, MR Carabasi, MH Coutre, SE Erba, HP Estey, E Glenn, MJ Kraut, EH Maslak, P Millenson, M Miller, CB Saba, HI Stone, R Tallman, MS
Citation: Mr. O'Donnell et al., NCCN Practice Guidelines for acute myelogenous leukemia, ONCOLOGY-NY, 14(11A), 2000, pp. 53-61
Underwater shock measurements using a ruby pressure gauge
Authors: Pangilinan, GI Russell, TP Baer, MR Namkung, J Chambers, P
Citation: Gi. Pangilinan et al., Underwater shock measurements using a ruby pressure gauge, APPL PHYS L, 77(5), 2000, pp. 684-686
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
Authors: Byrd, JC Dodge, RK Carroll, A Baer, MR Edwards, C Stamberg, J Qumsiyeh, M Moore, JO Mayer, RJ Davey, F Schiffer, CA Bloomfield, CD
Citation: Jc. Byrd et al., Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered, J CL ONCOL, 17(12), 1999, pp. 3767-3775
JCZS: An intermolecular potential database for performing accurate detonation and expansion calculations
Authors: Hobbs, ML Baer, MR McGee, BC
Citation: Ml. Hobbs et al., JCZS: An intermolecular potential database for performing accurate detonation and expansion calculations, PROP EXPL P, 24(5), 1999, pp. 269-279
A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia
Authors: Berstein, SH Fay, J Frankel, S Christiansen, N Baer, MR Jacobs, C Blosch, C Hanna, R Herzig, G
Citation: Sh. Berstein et al., A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia, CANC CHEMOT, 43(2), 1999, pp. 141-144
Uncommon patterns of presentation of leukemia (Reprinted from Textbook of Uncommon Cancer Second Edition)
Authors: Vidal, C Baer, MR Bloomfield, CD
Citation: C. Vidal et al., Uncommon patterns of presentation of leukemia (Reprinted from Textbook of Uncommon Cancer Second Edition), HEMATOL ONC, 17(1), 1999, pp. 11-29
Thrombopoietin receptor in acute myeloid leukemia
Authors: Wetzler, M Baer, MR
Citation: M. Wetzler et Mr. Baer, Thrombopoietin receptor in acute myeloid leukemia, LEUK RES, 23(2), 1999, pp. 191-194
Risultati: 1-16 |